Abstract
The article is devoted to assessing the influence of genetic polymorphisms of CYP2C9 and VKORC1 on warfarin dosing in patients with permanent form of atrial fibrillation. Studied were 100 patients with coronary heart disease and permanent form of atrial fibrillation, mean age 60,5±5,8 years. In patients with permanent form of atrial fibrillation genotypes CYP2C9*1/*3, TT and GG genotypes of VKORC1 are associated with low warfarin dose. Genotype CYP2C9*1/*3 increases the risk of bleeding complications during warfarin therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
